+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration



Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration



American Journal of Ophthalmology 136(6): 1049-1061



PURPOSE: To determine the effect and safety of verteporfin therapy (Visudyne) in Japanese age-related macular degeneration (AMD) patients. DESIGN: Open-label, multicenter, prospective, noncontrolled study. METHODS: The setting was five university hospitals in Japan. The study population was patients at least 50 years old, with best-corrected visual acuity of 20/40 to 20/200 inclusive and fluorescein angiography documenting subfoveal, classic-containing choroidal neovascularization (CNV) secondary to AMD and a lesion of greatest linear dimension ltoreq5,400 mum. For the intervention, patients received verteporfin intravenously followed by light administration 15 minutes after the infusion start. Additional treatment was given every 3 months through month 9 if leakage from CNV was observed on angiogram. The main outcome measure was percentage of lesions with progression of classic CNV beyond the area of the baseline lesion. RESULTS: Sixty-four patients were enrolled at five centers, and 61 patients completed the study. The median number of treatments given during the trial was three. At the 12-month examination, 12 patients (19%; 95% confidence interval: 11%-31%) had progression of classic CNV whereas 32 (50%) and 49 (77%) patients had no leakage from classic or occult CNV, respectively. The median visual acuity score (approximate Snellen equivalent) from baseline to month 12 increased from 50.0 (20/100)-56.5 (20/80+2) letters. Fourteen patients (22%) had visual disturbances, including two patients (3%) with acute vision decrease considered as serious adverse events and one patient (2%) with infusion-related back pain. No photosensitivity reactions were reported. CONCLUSIONS: Verteporfin therapy for subfoveal CNV in these Japanese patients appeared to have a similar or better angiographic and vision effect as that observed in Caucasian patients, with the same safety profile, supporting its use in Japanese patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012246006

Download citation: RISBibTeXText

PMID: 14644215

DOI: 10.1016/s0002-9394(03)00576-2


Related references

Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD): results of the Japanese AMD Trial (JAT) extension. Japanese Journal of Ophthalmology 52(2): 99, 2008

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration using verteporfin Safety results from an expanded access study, the verteporfin in age-related macular degeneration trial. IOVS 42(4): S305, 2001

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina 24(1): 1-12, 2004

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Archives of Ophthalmology 117(10): 1329-1345, 1999

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. American Journal of Ophthalmology 131(5): 541-560, 2001

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. American Journal of Ophthalmology 133(1): 168-169, 2002

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration using verteporfin Two-year results VIP report 5. IOVS 42(4): S304, 2001

Photodynamic therapy with verteporfin in Belgian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Bulletin de la Societe Belge d'Ophtalmologie 2006(299): 57-64, 2006

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Archives of Ophthalmology 119(2): 198-207, 2001

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration using verteporfin Two year results of 2 randomized clinical trials TAP report 5. IOVS 41(4): S532, 2000

Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients. Chinese Journal of Ophthalmology 43(3): 198-205, 2007

Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration: results of an effectiveness study. Archives of Ophthalmology 122(6): 853-856, 2004

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Archives of Ophthalmology 123(4): 448-457, 2005

Photodynamic therapy with verteporfin of predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration Evaluation of the efficacy and safety in the VIT study. IOVS 42(4): S439, 2001

Photodynamic therapy with verteporfin of subfoveal choroidal neovascularization in age-related macular degeneration Study design and baseline characteristics the VIP randomized clinical trial. IOVS 40(4): S321, 1999